Literature DB >> 9916062

Pathophysiology of antigen 85 in patients with active tuberculosis: antigen 85 circulates as complexes with fibronectin and immunoglobulin G.

S I Bentley-Hibbert1, X Quan, T Newman, K Huygen, H P Godfrey.   

Abstract

Antigen 85 (Ag85) complex proteins are major secretory products of Mycobacterium tuberculosis and induce strong cellular and humoral immune responses in infected experimental animals and human beings. We have previously shown that nanogram doses of these 30- to 32-kDa fibronectin-binding proteins inhibit local expression of delayed hypersensitivity by a T-cell fibronectin-dependent mechanism. Circulating levels of Ag85 might be expected to be elevated in patients with active tuberculosis and possibly to play a role in systemic anergy in these patients. To test this hypothesis, Ag85 was measured in serum and urine by a monoclonal antibody-based dot immunobinding assay in 56 patients and controls with known skin test reactivity. Median serum Ag85 levels were 50- to 150-fold higher in patients with active tuberculosis than in patients with active M. avium-intracellulare disease or other nontuberculous pulmonary disease or in healthy controls (P < 0.001). The median and range of serum Ag85 in patients with active tuberculosis was not significantly different between skin test-positive and -negative subjects. Patients with active M. avium disease could be distinguished from those with disease due to M. tuberculosis by monoclonal anti-Ag85 antibodies of appropriate specificities. No increases in urinary Ag85 were detected in any patient, regardless of the Ag85 level in serum. Chromatographic analysis and immunoprecipitation studies of serum revealed that Ag85 existed in the serum of these patients complexed to either fibronectin or immunoglobulin G (IgG). Uncomplexed circulating Ag85 was demonstrable in serum from fewer than 20% of patients with active tuberculosis. In patients with active tuberculosis, Ag85 is therefore likely to circulate primarily as complexes with plasma fibronectin and IgG rather than in unbound form. The existence of Ag85 complexes with plasma proteins would account for its lack of urinary clearance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9916062      PMCID: PMC96358     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  The global tuberculosis situation and the new control strategy of the World Health Organization.

Authors:  A Kochi
Journal:  Tubercle       Date:  1991-03

2.  A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction.

Authors:  D Bocart; D Lecossier; A De Lassence; D Valeyre; J P Battesti; A J Hance
Journal:  Am Rev Respir Dis       Date:  1992-05

3.  Association of the mycobacterial 30-kDa region proteins with the cutaneous infiltrates of leprosy lesions. Evidence for the involvement of the major mycobacterial secreted proteins in the local immune response of leprosy.

Authors:  A Rambukkana; P K Das; S Krieg; W R Faber
Journal:  Scand J Immunol       Date:  1992-07       Impact factor: 3.487

4.  Demonstration of tuberculostearic acid in sputum from patients with pulmonary tuberculosis by selected ion monitoring.

Authors:  G Odham; L Larsson; P A Mårdh
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

5.  T cell response to purified filtrate antigen 85 from Mycobacterium bovis Bacilli Calmette-Guérin (BCG) in leprosy patients.

Authors:  P Launois; K Huygen; J De Bruyn; M N'Diaye; B Diouf; L Sarthouj; J Grimaud; J Millan
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

6.  Detection of lipoarabinomannan as a diagnostic test for tuberculosis.

Authors:  E Sada; D Aguilar; M Torres; T Herrera
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

7.  Modulation of expression of delayed hypersensitivity by mycobacterial antigen 85 fibronectin-binding proteins.

Authors:  H P Godfrey; Z Feng; S Mandy; K Mandy; K Huygen; J De Bruyn; C Abou-Zeid; H G Wiker; S Nagai; H Tasaka
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

8.  Human immune response to Mycobacterium tuberculosis antigens.

Authors:  D V Havlir; R S Wallis; W H Boom; T M Daniel; K Chervenak; J J Ellner
Journal:  Infect Immun       Date:  1991-02       Impact factor: 3.441

9.  Isoelectrophoretic characterization of protein antigens present in mycobacterial culture filtrates and recognized by monoclonal antibodies directed against the Mycobacterium bovis BCG antigen 85 complex.

Authors:  A Drowart; J De Bruyn; K Huygen; G Damiani; H P Godfrey; M Stelandre; J C Yernault; J P Van Vooren
Journal:  Scand J Immunol       Date:  1992-11       Impact factor: 3.487

Review 10.  The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis.

Authors:  H G Wiker; M Harboe
Journal:  Microbiol Rev       Date:  1992-12
View more
  22 in total

1.  Use of an electronic nose to diagnose Mycobacterium bovis infection in badgers and cattle.

Authors:  R Fend; R Geddes; S Lesellier; H-M Vordermeier; L A L Corner; E Gormley; E Costello; R G Hewinson; D J Marlin; A C Woodman; M A Chambers
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

2.  Selection of DNA aptamers against Mycobacterium tuberculosis Ag85A, and its application in a graphene oxide-based fluorometric assay.

Authors:  Najmeh Ansari; Kiarash Ghazvini; Mohammad Ramezani; Mahin Shahdordizadeh; Rezvan Yazdian-Robati; Khalil Abnous; Seyed Mohammad Taghdisi
Journal:  Mikrochim Acta       Date:  2017-12-05       Impact factor: 5.833

3.  Salmonella enterica serovar Typhi O:1,9,12 polysaccharide-protein conjugate as a diagnostic tool for typhoid fever.

Authors:  Jessica Zuñiga; Luis Lillo; Junghee J Shin; Rajya L Machavarapu; Teresa Quiroga; Manuela Goycoolea; Betty Matsuhiro; L Aron-Hott; Henry P Godfrey; Felipe C Cabello
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

4.  Purification and immunoreactivity of three components from the 30/32-kilodalton antigen 85 complex in Mycobacterium tuberculosis.

Authors:  J H Lim; J K Park; E K Jo; C H Song; D Min; Y J Song; H J Kim
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

5.  Diagnostic value of early secreted antigenic target-6 for the diagnosis of tuberculous meningitis patients.

Authors:  R S Kashyap; S S Ramteke; S H Morey; H J Purohit; G M Taori; H F Daginawala
Journal:  Infection       Date:  2009-12       Impact factor: 3.553

6.  Cloning of the gene encoding a 22-kilodalton cell surface antigen of Mycobacterium bovis BCG and analysis of its potential for DNA vaccination against tuberculosis.

Authors:  P Lefèvre; O Denis; L De Wit; A Tanghe; P Vandenbussche; J Content; K Huygen
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

7.  Combinatorial use of antibodies to secreted mycobacterial proteins in a host immune system-independent test for tuberculosis.

Authors:  C P Landowski; H P Godfrey; S I Bentley-Hibbert; X Liu; Z Huang; R Sepulveda; K Huygen; M L Gennaro; F H Moy; S A Lesley; M Haak-Frendscho
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

8.  Mycobacterium tuberculosis binding to human surfactant proteins A and D, fibronectin, and small airway epithelial cells under shear conditions.

Authors:  Luanne Hall-Stoodley; Gayle Watts; Joy E Crowther; Ashwin Balagopal; Jordi B Torrelles; James Robison-Cox; Robert F Bargatze; Allen G Harmsen; Erika C Crouch; Larry S Schlesinger
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

9.  The domains of human fibronectin mediating the binding of alpha antigen, the most immunopotent antigen of mycobacteria that induces protective immunity against mycobacterial infection.

Authors:  M Naito; T Fukuda; K Sekiguchi; T Yamada
Journal:  Biochem J       Date:  2000-05-01       Impact factor: 3.857

10.  Portrait of a pathogen: the Mycobacterium tuberculosis proteome in vivo.

Authors:  Nicole A Kruh; Jolynn Troudt; Angelo Izzo; Jessica Prenni; Karen M Dobos
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.